Gardiquimod
Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs) . Gardiquimod specifically activates TLR7 at concentrations below 10 μM.
Product Specifications
CAS Number
1020412-43-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/gardiquimod.html
Concentration
10mM
Purity
99.91
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC(C)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N
Molecular Formula
C17H23N5O
Molecular Weight
313.40
Precautions
H302, H315, H319, H335
References & Citations
[1]Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29 (6) :907-18.|[2]Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369 (2) :298-306.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HIV-1; TLR7; TLR8
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
038035-ML750 100 µL
LYSMD1, CT (LYSMD1, LysM and putative peptidoglycan-binding domain-containing protein 1) (MaxLight 750) discontinued
Sign In for Pricing
View Details 